GSK Malaria Vaccine Given Approval By European Regulators
Pharmaceutical giant GlaxoSmithKline with the backing of the Gates Foundation are set to make history as their vaccine, Mosquirix, has received the approval of European Medicines Agency (EMA).
It took 30 years to develop Mosquirix and even with the approval of the EMA, the vaccine is unlikely to be available commercially for another year and a half. It still requires the approval of the World Health Organisation (WHO).
The vaccine is not created for profit, GSK has revealed and this comes as a relief to Sub-saharan Africa where Malaria is the biggest killer.